2 hours BTIG Research Reiterates “Buy” Rating for Nektar Therapeutics (NASDAQ:NKTR) MarketBeat
BTIG Research restated a “buy” rating and issued a $4.00 price target on shares of Nektar Therapeutics in a research note on Monday.
Nasdaq 100 · Nektar (NKTR) · Science